Ayşe KAMAN, Türkan AYDIN-TEKE, Fatma Nur ÖZ, GÜLSÜM İCLAL BAYHAN, ÖZGE METİN AKCAN, ZEYNEP GÖKÇE GAYRETLİ AYDIN, Gönül TANIR

A pediatric case of acute meningitis due to Streptococcus pneumoniae serotype 33D

Streptococcus pneumoniae is a leading cause of bacterial meningitis in children. It is also responsible for bacteremia, sepsis, pneumonia, sinusitis and acute otitis media in young children worldwide. The serotypes included in the 7-valent conjugated pneumococcal vaccine (PCV7)--1, 5, 6A, 6B, 14, 19F, 23F--are those most commonly responsible for invasive pneumococcal disease (IPD) globally. Unvaccinated children are at greater risk for meningitis. The rate of non-vaccine serotypes as causes of invasive disease has increased. Although the incidence rate of IPD is highest in children aged <2 years, the rare, non-vaccine serotypes of S. pneumoniae may be responsible for acute meningitis in older, unvaccinated children. In this report, we present a pediatric case of meningitis due to S. pneumoniae serotype 33D, which has not been previously identified as a cause of IPD in those countries where PCV7 is routinely administered, including Turkey.

PDF

___

1. Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics 2010; 125: 1020-1030.

2. Echtler K, Stark K, Lorenz M, et al. Platelets contribute to postnatal occlusion of the ductus arteriosus. Nat Med 2010; 16: 75-82.

3. Clyman R, Chemtob S. Vessel remodeling in the newborn: platelets fill the gap. Nat Med 2010; 16: 33-35.

4. Shah NA, Hills NK, Waleh N, et al. Relationship between circulating platelet counts and ductus arteriosus patency after indomethacin treatment. J Pediatr 2011; 158: 919-923.

5. Alyamac Dizdar E, Ozdemir R, Sari FN, et al. Low platelet count is associated with ductus arteriosus patency in preterm newborns. Early Hum Dev 2012; 88: 813-816.

6. Sallmon H, Weber SC, Hüning B, et al. Thrombocytopenia in the first 24 hours after birth and incidence of patent ductus arteriosus. Pediatrics 2012; 130: e623-e630.

7. Fujioka K, Morioka I, Miwa A, et al. Does thrombocytopenia contribute to patent ductus arteriosus? Nat Med 2011; 17: 29-30.

8. Dani C, Poggi C, Fontanelli G. Relationship between platelet count and volume and spontaneous and pharmacological closure of ductus arteriosus in preterm infants. Am J Perinatol 2013; 30: 359-364.

9. Antoniades HN. PDGF: A multifunctional growth factor. Baillieres Clin Endocrinol Metab 1991; 5: 595-613.

10. Bowen-Pope DF, Raines EW. History of discovery: platelet-derived growth factor. Arterioscler Thromb Vasc Biol 2011; 31: 2397-2401.

11. Hoch RV, Soriano P. Roles of PDGF in animal development. Development 2003; 130: 4769-4784.

12. Heldin CH, Ostman A, Rönnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1998; 1378: F79-F113.

13. Baumgartner HR, Hosang M. Platelets, platelet-derived growth factor and arteriosclerosis. Experientia 1988; 44: 109-112.

14. Li C, Li J, Li Y, et al. Crosstalk between platelets and the immune system: old systems with new discoveries. Adv Hematol 2012; 2012: 384685.

15. Coceani F, Baragatti B. Mechanisms for ductus arteriosus closure. Semin Perinatol 2012; 36: 92-97.

16. Bökenkamp R, DeRuiter MC, van Munsteren C, Gittenberger-de Groot AC. Insights into the pathogenesis and genetic background of patency of the ductus arteriosus. Neonatology 2010; 98: 6-17.

17. Clyman RI. Mechanisms regulating the ductus arteriosus. Biol Neonate 2006; 89: 330-335.

18. Engür MA, Engür D. Platelet-rich plasma for patent ductus arteriosus: an orthopaedic surgeon's perspective. Cardiol Young 2014; 24: 385-387.

19. Lin F, Zhu J, Tonnesen MG, et al. Fibronectin peptides that bind PDGF-BB enhance survival of cells and tissue under stress. J Invest Dermatol 2014; 134: 1119-1127.

20. Weber SC, Gratopp A, Akanbi S, et al. Isolation and culture of fibroblasts, vascular smooth muscle, and endothelial cells from the fetal rat ductus arteriosus. Pediatr Res 2011; 70: 236-241.

21. Seppä H, Grotendorst G, Seppä S, Schiffmann E, Martin GR. Platelet-derived growth factor in chemotactic for fibroblasts. J Cell Biol 1982; 92: 584-588.

22. Heldin P, Asplund T, Ytterberg D, Thelin S, Laurent TC. Characterization of the molecular mechanism involved in the activation of hyaluronan synthetase by platelet-derived growth factor in human mesothelial cells. Biochem J 1992; 283: 165-170.

23. McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed 2007; 92: F424-F427.

13. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013; 62: 521-524.

14. Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32: 203-207